Poor
Mostly Not Aligned
Patient Risk:
Moderate
Summary
Many safety/interaction and efficacy-related claims are not supported by the provided label excerpts (or are not adequately specified). Several adverse-effect and interaction statements conflict with the label’s described adverse reactions (common adverse reactions differ), and multiple interaction claims are absent from the supplied label text.
Category Scores
Accurate Statements
Vascepa (icosapent ethyl) is indicated to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) with established cardiovascular disease or diabetes plus additional cardiovascular risk factors (as an adjunct to maximally tolerated statin therapy).
Section 1 INDICATIONS AND USAGE (first bullet).
Vascepa is indicated as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.
Section 1 INDICATIONS AND USAGE (second bullet).
VASCEPA contains ethyl esters of omega-3 fatty acid, eicosapentaenoic acid (EPA), obtained from the oil of fish.
Section 5.2 Potential for Allergic Reactions in Patients with Fish Allergy.
VASCEPA is associated with an increased risk of bleeding.
Section 5.3 Bleeding.
Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time; patients receiving VASCEPA with concomitant anticoagulants and/or antiplatelet agents should be monitored for bleeding.
Section 7.1 Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents.
Common adverse reactions (incidence ≥3% on VASCEPA and ≥1% more frequent than placebo) included musculoskeletal pain, peripheral edema, constipation, gout, and atrial fibrillation.
Section 6.1 Clinical Trials Experience (Common adverse reactions...).
VASCEPA works by reducing hepatic very low-density lipoprotein triglyceride (VLDL-TG) synthesis and/or secretion and enhancing TG clearance from circulating VLDL particles (studies suggest).
Section 12.1 Mechanism of Action (first paragraph).
Unsupported Statements
Vascepa (icosapent ethyl) is a prescription medication used to lower triglyceride levels in the blood.
Supported for reducing TG levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia, but the statement is general and does not match the label’s specific indication population/severity provided.
Vascepa works by inhibiting the production of triglycerides in the liver.
The label excerpt describes reduction of VLDL-TG synthesis and/or secretion and enhanced TG clearance; it does not state triglyceride production inhibition in the liver as phrased.
Taking Vascepa with blood thinners (such as warfarin, aspirin, and heparin) can increase the risk of bleeding.
The provided interaction/bleeding guidance names monitoring with anticoagulants/antiplatelet agents and states incidence is greater with concomitant antithrombotic medications such as aspirin, clopidogrel, or warfarin. It does not specifically mention heparin in the supplied excerpts.
Taking Vascepa with anti-inflammatory medications (NSAIDs) such as ibuprofen or naproxen can increase the risk of bleeding.
No NSAID-specific bleeding interaction is present in the supplied label excerpts.
Taking Vascepa with statins (such as atorvastatin or simvastatin) can increase the risk of muscle damage.
The supplied excerpts do not mention any muscle-damage risk or statin-specific interaction.
Taking Vascepa with metformin can increase the risk of lactic acidosis.
No metformin interaction or lactic acidosis risk is present in the supplied label excerpts.
Antacids (such as Tums and Rolaids) can decrease the absorption of Vascepa, reducing its effectiveness.
No antacid-specific absorption interaction is present in the supplied label excerpts.
Proton pump inhibitors (such as omeprazole and lansoprazole) can decrease the absorption of Vascepa, reducing its effectiveness.
No PPI-specific absorption interaction is present in the supplied label excerpts.
Cholestyramine (Questran) can decrease the absorption of Vascepa, reducing its effectiveness.
No cholestyramine-specific absorption interaction is present in the supplied label excerpts.
The most common side effects of Vascepa include nausea, vomiting, diarrhea, and abdominal pain.
The supplied label excerpt lists common adverse reactions as musculoskeletal pain, peripheral edema, constipation, gout, and atrial fibrillation; diarrhea and abdominal discomfort are mentioned only in postmarketing, not as “most common.”
It is not recommended to take Vascepa with other omega-3 fatty acid supplements because this can increase the risk of bleeding.
No label excerpt provided supports a recommendation against other omega-3 supplements for bleeding risk.
Vascepa is not recommended for use in people with a history of bleeding disorders because it can increase the risk of bleeding.
The supplied contraindications excerpt is limited to hypersensitivity, and the bleeding warning excerpt does not define or restrict use based on “history of bleeding disorders.”
Vascepa is not recommended for use during pregnancy.
No pregnancy guidance is present in the supplied label excerpts.
Vascepa is not recommended for use during breastfeeding.
No breastfeeding guidance is present in the supplied label excerpts.
Vascepa is described as able to be taken with other medications for high cholesterol, but potential interactions should be discussed with a doctor or pharmacist.
The supplied excerpts do not state “able to be taken with other medications for high cholesterol” nor provide broad interaction counseling language; only statin use appears as part of an adjunct indication.
Contradictions
Important Omissions
Dose and administration instructions (4 g/day; specific capsule regimens; swallow whole; do not break open/crush/dissolve/chew) were not addressed by the AI claims provided.
Importance:
Moderate
Contraindication for hypersensitivity to VASCEPA or any components was not included; instead, the AI asserted bleeding-disorder history as a non-recommended condition (unsupported by the provided contraindication excerpt).
Importance:
Moderate
Label safety warning regarding atrial fibrillation/flutter requiring hospitalization was omitted from the AI claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements about bleeding interactions and adverse effects are not supported by the provided label excerpts, and pregnancy/breastfeeding recommendations are not supported (absent from supplied excerpts). This could mislead clinical decision-making or monitoring expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Not Aligned
Primary Issue
Multiple drug interaction, side-effect frequency, and pregnancy/breastfeeding statements are unsupported or not present in the supplied label excerpts, and common adverse reactions listed by the AI do not match the label-provided common adverse reactions.
Suggested Improvement
Limit claims to the provided label-supported indications, mechanism language, named bleeding risk/monitoring with anticoagulants/antiplatelet agents, and label-specified common adverse reactions; omit pregnancy/breastfeeding and NSAID/statin/metformin/antacid/PPI/cholestyramine interaction assertions unless supported by the actual full label text.